Anixa Biosciences, Inc. (ANIX)

Market Cap	95.62M
Revenue (ttm)	n/a
Net Income (ttm)	-12.48M
Shares Out	32.19M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,793
Open	3.060
Previous Close	3.080
Day's Range	2.910 - 3.080
52-Week Range	2.070 - 4.200
Beta	0.86
Analysts	Strong Buy
Price Target	9.00 (+203.03%)
Earnings Date	Mar 11, 2025

About ANIX

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the develo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 1, 1987
• Employees: 5
• Stock Exchange: NASDAQ
• Ticker Symbol: ANIX
• Website: https://www.anixa.com

Analyst Forecast

According to 3 analysts, the average rating for ANIX stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 203.03% from the latest price.

Price Target

$9.0

(203.03% upside)

Analyst Consensus: Strong Buy